Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 676 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... January 10, 2023 Selumetinib Approved by FDA to Treat Children with NF1 April 14, 2020 Diagnosed Alone October 6, 2020 Bride Cancels Engagement Photos To Share Special Dance With Terminal Dad. April 19, 2019 Load more HOT NEWS FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points... EMA Recommends Extension of Indications for Cabozantinib Foodie Fridays: Farmer’s Market Finds
